Thomas Meek Email and Phone Number
Thomas Meek work email
- Valid
- Valid
- Valid
Thomas Meek personal email
Experienced scientist identifying and validating novel targets for the treatment of metabolic disease. History of managing automation technologies to carryout unbiased, human centric, phenotypic screens. Background in in vivo pre-clinical pharmacological research into anti-obesity and anti-diabetic therapeutics, with a focus on peptide and proteins.
-
Sr. Director Of Cardiometabolic DisordersAmgenThousand Oaks, Ca, Us -
Senior Director - Cardiometabolic DisordersAmgen Jul 2024 - PresentThousand Oaks, Ca, UsThe Metabolic team strives to innovate in two corresponding arenas. The first is by providing a source of novel, validated targets for entry into the organization’s portfolio through the use of advanced in vitro models, sophisticated genetics, and functional genomics screening. Second, by progressing programs that take advantage of specialized teams to engineer a broad array of drug modalities including bispecific mABS, mAB-peptide conjugates, siRNAs, peptide/protein fusions, molecular glues, and DNA encoded libraries.
-
Director Of Technology And GenomicsNovo Nordisk Nov 2020 - Jul 2024Bagsværd, DkWe aim to establish and apply state-of-the-art genomics and screening technologies to discover and validate novel therapeutic targets for cardiometabolic diseases using human-centric in vitro approaches. The department is a dedicated, collaborative team, working within a variety of advanced technologies, including high throughput screening, high content imaging, single-cell sequencing, CRISPR editing, functional genomics, proteomics, peptidomics, and statistical modelling. Together, we share a passion for translational research and a desire to discover new scientific paths to improve the lives of patients. Ultimately, our goal is to identify targets and key biology to discover new disruptive therapeutics. -
Associate Director - Discovery BiologyNovo Nordisk Dec 2019 - Nov 2020Bagsværd, DkThe Discovery Biology group within Novo Nordisk's Obesity Research Unit develops strategies for identifying novel platforms or pathways that advance our understanding of the pathophysiology of obesity and thereby provides an entry point to generate new therapeutics in this space. In addition, the team works to provide developmental support for active research programs through technical expertise in bioinformatics, proteomics, histology, cell-based screening tools, and flow cytometry.
-
Manager - Discovery BiologyNovo Nordisk Oct 2018 - Dec 2019Bagsværd, Dk
-
Research ScientistNovo Nordisk Mar 2016 - Sep 2018Bagsværd, DkIn vivo pharmacology and safety support for early stage development of potential obesity and diabetes treatments. Act as Lead Biologist on various drug discovery projects involving peptide or peptide/small molecule combinations.
-
Assistant ProfessorUniversity Of Washington Medical Center 2015 - 2016Seattle, Washington, UsIndependent research program investigating physiological mechanisms underlying energy regulation and the pathogenesis of uncontrolled diabetes mellitus. Major questions under investigation included 1) by what mechanisms do circulating signals involved in the regulation of metabolism, including hormones and nutrients, influence energy expenditure and food intake? 2) Which specific hypothalamic pathways are sensitive to the actions of these signals? 3) What peripheral systems contribute to diabetic hyperglycemia and can the dysregulation be reversed? -
Postdoctoral FellowUniversity Of Washington Nov 2011 - 2015Seattle, Wa, UsElucidation of the neuroendocrine contributors to diabetic hyperglycemia. This work has aimed, in part, at understanding the metabolic actions of the adipocyte derived hormone leptin and its potential as an independent, or adjunct therapy, to either insulin or GLP-1 agonists in the setting of uncontrolled diabetes or diet-induced obesity.Commonly employed approaches included: insulin-dependent and –independent glucose disposal through the use of classic glucose 'clamps', frequently sampled intravenous tolerance tests, and radioactive 2-deoxyglucose tracer techniques. Additionally, in an effort to identify neuronal targets for the treatment of homeostatic pathophysiologies, virally mediated techniques such as optogenetics and DREADDs were applied.Mentors: Dr. Michael Schwartz and Dr. Gregory Morton
Thomas Meek Skills
Thomas Meek Education Details
-
University Of California, RiversideExercise Physiology -
University Of DelawareAnimal Physiology
Frequently Asked Questions about Thomas Meek
What company does Thomas Meek work for?
Thomas Meek works for Amgen
What is Thomas Meek's role at the current company?
Thomas Meek's current role is Sr. Director of Cardiometabolic Disorders.
What is Thomas Meek's email address?
Thomas Meek's email address is thmeek@uw.edu
What schools did Thomas Meek attend?
Thomas Meek attended University Of California, Riverside, University Of Delaware.
What skills is Thomas Meek known for?
Thomas Meek has skills like Diabetes, Physiology, Animal Models, Endocrinology, Drug Discovery, Metabolic Syndrome, Obesity Theraputics, Pharmacology, In Vivo, Drug Development, Peptides, Life Sciences.
Who are Thomas Meek's colleagues?
Thomas Meek's colleagues are Hermineh Aghanian, Gary Tung, Almha Gilheany, Burak Çetinkaya, Bina Patel, Katherine Cleland, Liz Chrencik Djaraher.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial